Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2008-09-30
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Summary Background Data: Very few prospective uncontrolled studies have investigated the effects of Roux-en-Y gastric bypass (RYGB) on cardiovascular risk factors. No controlled studies had as primary goal the changes in HDL-cholesterol after gastric bypass.
Methods: Forty subjects with a BMI\>40 or ≥35 kg/m2 in the presence of diabetes were enrolled.
Twenty of them were operated of RYGB while 20 received lifestyle modification suggestions and medical therapy for obesity complications (diabetes, hypertension and hyperlipidemia).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of the study related to the changes in HDL-cholesterol at 1 year after the intervention. Secondary aims were the changes in Apolipoprotein 4 (Apo4) and insulin sensitivity after the interventions.
Twenty morbidly-obese subjects (11 women and 9 men), whose 14 with normal glucose tolerance and 6 with type 2 diabetes mellitus (T2DM), have been studied before and 1, 2, 3, 6, 9 and 12 months after bariatric surgery.
Twenty morbidly-obese subjects (12 women and 8 men), 15 with normal glucose tolerance and 5 with T2DM, in the waiting list for bariatric surgery were enrolled in the protocol and underwent medical therapy for obesity complications (diabetes, hypertension and hyperlipidemia) and lifestyle modification suggestions.
Participants were eligible for inclusion if they had a BMI of 40 kg/m2 or \>35 kg/m2 in presence of type 2 diabetes, were aged 30 to 60 years, and had not sustained weight loss in the previous 1 year. Exclusion criteria were a history of major abdominal or bariatric surgery, disabling cardiac or pulmonary diseases, cancer, long-term treatment with oral corticosteroids, and mental illness.
Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume usually \< 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament , through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 150 cm from the gastrojejunostomy.
Lifestyle modifications A hypocaloric diet (15 kcal/kgbw containing 55% carbohydrates, 30% lipids and 15% proteins) was prescribed together with the indications to perform 30 minutes brisk walk each day. Patients had open access to a diabetologist every 3 months. Medical therapies, including pharmaceutical agents, were assigned on an individual basis.
Anthropometric measures Body weight was measured to the nearest 0.1 kg with a beam scale and height to the nearest 0.5 cm using a stadiometer (Holatin, Crosswell, Wales, U.K.).
Blood pressure Blood pressure was measured 3 times with an appropriately sized cuff after the participant had rested for 5 minutes, and the last 2 measurements were averaged.
Oral glucose tolerance test A standard 75-g oral glucose tolerance test (OGTT) was performed after an overnight fasting with blood sampling at 0, 30, 60, 90, 120, and 180 min. Samples were placed in chilled tubes, and plasma was separated within 20 min and stored at -80°C.
Analytical methods Blood was drawn in the morning after an overnight fast. The sera and plasma were immediately separated by centrifugation at 4°C and stored at -80°C until assay.
Plasma glucose was measured by the glucose-oxidase method (Beckman, Fullerton, CA). Plasma insulin was assayed by microparticle-enzyme immunoassay (Abbott, Pasadena, CA) with a sensitivity of 1 μU/ml and an intra-assay CV of 6.6%.
Total cholesterol and triglycerides were measured enzymatically. HDL-cholesterol was measured after precipitating apolipoprotein B-containing lipoproteins with dextran sulfate and magnesium chloride.
HbA1c serum levels were measured by high-performance liquid-chromatography (normal range 3.5-6.5%) Apo A4 was assessed by ELISA (Cusabio Biotech, Wuhan, Hubei, China); the detection range is from 15.62 μg/l to 1000 μg/l and the minimum detectable concentration is 4 μg/l.
Insulin Sensitivity Models
The OGTT and fasting plasma glucose and insulin were used to compute the insulin sensitivity. Insulin resistance was assessed using the homeostasis model assessment (HOMA-IR) originally described by Mathew et al. HOMA-IR was calculated using the following equation:
HOMA-IR(μU/ml∙mg/dl)=fasting insulin(μU/ml)∙(fasting glucose (mg/dl))/405 Peripheral insulin sensitivity was assessed by the Oral Glucose Insulin Sensitivity (OGIS) model. OGIS is an index of insulin sensitivity calculated in this case from the 3 hours OGTT and it is an estimate of the glucose clearance during a hyperinsulinemic euglycemic glucose clamp expressed in ml/min per square meter of body surface area.
Statistics All of the data are expressed as means ± SD unless otherwise specified. The Wilcoxon paired-sample test was used for intragroup comparisons. Two-sided P \< 0.05 was considered significant. Nonparametric Spearman correlations were used to assess linear relationships between single variables.
We calculated that a total of 30 participants would give 80% power to detect a significant (P \< 0.05) difference between the groups. To allow for possible dropouts and add power for analysis of secondary outcomes, we decided to enroll 40 participants.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Roux-en-Y gastric bypass
Both sexes, age between 30 and 60 years, BMI =/\> 35 kg/m2
Roux-en-Y gastric bypass
Active Comparator: Roux-en-Y gastric bypass
diet and lifestyle modifications
Both sexes, age between 30 and 60 years, BMI =/\> 35 kg/m2
diet and lifestyle modifications
Active Comparator: diet and lifestyle modifications
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Roux-en-Y gastric bypass
Active Comparator: Roux-en-Y gastric bypass
diet and lifestyle modifications
Active Comparator: diet and lifestyle modifications
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 30-60 years,
* both sexes
Exclusion Criteria
* disabling cardiac or pulmonary diseases,
* cancer,
* long-term treatment with oral corticosteroids, and
* mental illness
30 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Catholic University of the Sacred Heart
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Geltrude Mingrone
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Geltrude Mingrone, MD
Role: PRINCIPAL_INVESTIGATOR
Catholic University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Catholic University
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Raffaelli M, Guidone C, Callari C, Iaconelli A, Bellantone R, Mingrone G. Effect of gastric bypass versus diet on cardiovascular risk factors. Ann Surg. 2014 Apr;259(4):694-9. doi: 10.1097/SLA.0b013e31829d6989.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HDL-2008
Identifier Type: -
Identifier Source: org_study_id